CISO appointment
Siwar El Assad named Chief Information Security Officer at QuantHealth
Siwar El Assad is the Chief Information Security Officer of QuantHealth.
Records: QuantHealth · Siwar El Assad
| Person | Siwar El Assad |
|---|---|
| New role | Chief Information Security Officer |
| Company | QuantHealth |
| Announced | January 13, 2025 |
| Added to the record | September 30, 2026 |
| Source | Business Wire (company announcement) |
Context from the record
- QuantHealth is filed under Healthcare, Asia-Pacific, on our record.
What this move signals
QuantHealth named Siwar El Assad as Chief Information Security Officer as part of a leadership team expansion. She began her career at Check Point Software Technologies before moving into cybersecurity leadership roles across the technology and healthcare sectors.
What the sources say
El Assad's focus as Chief Information Security Officer will include safeguarding sensitive clinical trial data, elevating the company's data security protocols and ensuring compliance with industry standards, the release says. The company says the leadership expansion will enhance its security infrastructure and advance the QuantHealth Clinical Development OS, its existing SaaS platform.
The release says El Assad brings experience in offensive and defensive security to QuantHealth.
Orr Inbar, CEO and Co-Founder of QuantHealth, said the company has developed partnerships with pharmaceutical companies since its 2022 launch into the U.S. market. The company says that in this new stage of growth it is focusing on deployment capabilities and on data and systems integration with its pharma customers. The release says the announcement follows QuantHealth's publication of simulated clinical trial outcomes that showed 85 percent accuracy across 100 trials.
The company says its Clinical-Simulator predicts each trial patient's response to treatment, letting trial design teams predict how a whole clinical trial will play out. The company says its simulator is based on an AI engine and a dataset of over 700K therapeutics and 350m patients. According to the company, the updated solution is due to become available to users in early 2025. The company says it has Life-Science investors in Israel, Europe and the US, as well as an advisory board of physicians and scientists.
The Briefing
Every verified CISO move of the week, in your inbox Friday.
Every verified CISO move and one piece of analysis, weekly.
Unsubscribe any time. See the privacy policy.